Core Viewpoint - Zimmer Biomet is experiencing growth driven by strategic product launches and market expansion, particularly in emerging markets, despite facing macroeconomic challenges and operational pressures [2][8][9]. Group 1: Revenue Growth and Market Expansion - Strong revenue growth in emerging markets, particularly in the Asia Pacific region, is a key driver for Zimmer Biomet [2]. - The company is on a diversification journey with its S.E.T. business, expecting mid-single-digit sales growth to continue into 2025 and 2026 [3]. - Zimmer Biomet's international business exceeded sales expectations in the third quarter, supported by strong demand in reconstructive knees, hips, and S.E.T. categories [18]. Group 2: Product Launches and Market Share - The company anticipates significant market share gains from upcoming product launches, including the Oxford Partial cementless Knee and Z1 HAMMR in Europe [10]. - Zimmer Biomet has been witnessing strong market share gains in reconstructive knees and hips across key geographies [18]. Group 3: Financial Performance and Challenges - In the third quarter of 2024, Zimmer Biomet's net sales were negatively impacted by foreign exchange rates, with an expected adverse impact of 75 basis points for the full year [15]. - The company faced a 3.9% increase in the cost of products sold and a 3.1% rise in selling, general, and administrative expenses, leading to a contraction in adjusted gross and operating margins [12]. - Staffing shortages, supply chain issues, and geopolitical complications are creating significant pressure on revenues and operating profit [17].

WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Bio ...

WARSAW, Ind., Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30, 2024. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a com ...

Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration ("FDA") 510(k) clearance for the OsseoFit Stemless Shoulder System for total shoulder replacement. The system is designed to match the natural humeral (upper shoulder bone) anatomy to optimize anatomical fit while maximizing the preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company's expansive total shoulder portfolio. The company plans to launch the system commercially in the first quarter of ...

Company Developments - Zimmer Biomet Holdings Inc (ZBH) received FDA 510(k) clearance for its Persona SoluTion PPS Femur, a total knee implant component designed for patients with sensitivities to bone cement and/or metal [1] - The company expects to commercially launch Persona SoluTion PPS Femur in the United States in Q1 2025 [1] - ZBH recently received FDA Premarket Approval Application Supplement approval for the Oxford Cementless Partial Knee, making it the only FDA-approved cementless partial knee implant in the United States [8] Product Details - Persona SoluTion PPS Femur combines cementless fixation with PPS coating, providing initial scratch fit stability and supporting biological fixation through bony growth [5] - The implant minimizes common metal sensitizers by combining with Persona OsseoTi tibia and Vivacit-E Highly Crosslinked Polyethylene (HXLPE) [6] - The implant is made of Tivanium (Ti-6Al-4V) alloy with over 17 years of clinical use, treated with the Ti-Nidium Surface Hardening Process [6] Market Performance - ZBH shares moved 0.1% lower to $110.62 following the announcement [2] - The company has a market capitalization of $22.09 billion [3] - ZBH shares have lost 4.5% in the past year, compared to the industry's 21% growth [9] Financial Performance - ZBH's earnings surpassed estimates in three of the trailing four quarters, with an average surprise of 1.76% [3] Industry Outlook - The global knee replacement market is expected to reach $16.99 billion by 2031, growing at a CAGR of 5.67% during 2024-2031 [7] - Key growth drivers include rising incidence of osteoarthritis and increasing demand for joint replacement surgeries [7]

Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration (“FDA”) Premarket Approval Application (“PMA”) Supplement approval for the Oxford Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (“IDE”) study and non-clinical testing for cementless partial knee replacement (“PKR”).With this, Oxford Cementless Partial Knee becomes the only FDA-approved cementless partial knee implant in the United States. The latest FDA ...

WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. Persona Revision Knee System "After the successful introduction of Persona Revision Knee in the United States and other mar ...

Zimmer Biomet Holdings, Inc. (ZBH) posted third-quarter 2024 adjusted earnings per share (EPS) of $1.74, missing the Zacks Consensus Estimate by 0.6%. However, the adjusted figure increased 5.5% year over year. The quarter's adjustments included certain amortization, restructuring and other cost reduction initiatives and European Union Medical Device Regulation-related charges, among others. On a reported basis, the company registered earnings of $1.23 per share, compared to 77 cents in the year-ago period. ...

Financial Data and Key Metrics Changes - In Q3 2024, net sales were $1.824 billion, an increase of 4% on a reported basis and 4.1% excluding foreign currency impact [25] - Adjusted diluted earnings per share (EPS) was $1.74, compared to $1.65 in the prior year, indicating earnings grew faster than revenue [30] - Free cash flow for the quarter was $310 million, bringing year-to-date free cash flow to $652 million [32] Business Line Data and Key Metrics Changes - The combined knee and hip businesses, referred to as the reconstructed platform, grew in the mid-single-digit range globally, while the head segment delivered upper single-digit growth [9] - The S.E.T. segment grew 7.3%, led by CMFT, sports, and upper extremities, marking the fourth consecutive quarter of at least mid-single-digit growth [29] - The "other" category declined by 9.5%, primarily due to difficult comparisons from the prior year and ERP-related challenges [29] Market Data and Key Metrics Changes - The U.S. business grew by 2%, while international sales grew by 7.1%, with strength across knee and S.E.T. segments [26] - Global knees grew by 5.5%, with U.S. growth at 2.9% and international growth at 9.2% [26] - Global hips grew by 3.7%, with U.S. growth at 4.9% and international growth at 2.4% [27] Company Strategy and Development Direction - The company is focused on three strategic priorities: people and culture, operational excellence, and innovation and diversification [16] - The company plans to maintain mid-single-digit revenue growth and adjusted EPS growth of at least 1.5 times revenue through 2027 [19] - The innovation pipeline includes over 50 meaningful product launches, with a strong emphasis on the hips platform and robotics [11][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resolution of ERP challenges and anticipates returning to normal shipping levels by the end of 2024 [8] - The company expects continued market growth driven by an aging population and technological advancements [10] - Management remains optimistic about 2025, citing new product introductions and the resolution of ERP issues as key factors [42] Other Important Information - The company repurchased approximately $600 million in shares during Q3, with over $850 million repurchased through the end of October [33] - The company updated its 2024 guidance, expecting constant currency revenue growth of 4.25% to 4.75% [34] Q&A Session Summary Question: Why is the guidance cut more than the ERP issue for 2024? - Management indicated a conservative approach due to various factors, including pricing dynamics and recent disruptions [39] Question: What are the updated thoughts on M&A? - Management stated that while they do not need to pursue M&A to maintain growth, they are open to opportunities that make strategic and financial sense [45][46] Question: Can you provide insights into the reconstructive businesses, particularly knees? - Management confirmed recovery from previous supply chain issues and expressed optimism for knee performance moving forward [50] Question: What are the expectations for pricing in the U.S.? - Management noted positive pricing trends and structural improvements leading to better performance [86] Question: What impact is volume-based purchasing in China having? - Management reported that China represents 2% to 3% of global sales and has not significantly impacted revenue expectations [91]

For the quarter ended September 2024, Zimmer Biomet (ZBH) reported revenue of $1.82 billion, up 4% over the same period last year. EPS came in at $1.74, compared to $1.65 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.8 billion, representing a surprise of +1.12%. The company delivered an EPS surprise of -0.57%, with the consensus EPS estimate being $1.75.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...